Reuters logo
BRIEF-Radius Health says CHMP has issued second day-180 list of outstanding issues in its regulatory review of Eladynos
July 21, 2017 / 8:26 PM / 5 months ago

BRIEF-Radius Health says CHMP has issued second day-180 list of outstanding issues in its regulatory review of Eladynos

July 21 (Reuters) - Radius Health Inc:

* Radius health announces that the committee for medicinal products for human use (chmp) has issued a second day-180 list of outstanding issues in its regulatory review of Eladynos™ (abaloparatide-sc), a bone building agent for the treatment of postmenopausal women with osteoporosis at high risk for fracture

* Radius Health Inc - radius expects chmp to issue an opinion regarding maa for abaloparatide-sc prior to end of 2017.

* Radius health inc - if approved, abaloparatide-sc to be marketed in European union as eladynos Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below